Subsequent work revealed VP was unlikely to hold value for YAP–TEAD inhibition in cancer patients, as it is difficult to synthesize in large scale, has limited solubility and stability, requires high concentrations for anti-tumor effects, and has Hippo-independent effects [17,19,20]. The gene discussed is YAP1; the disease is cancer.